Last $113.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
AKBLF On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Berlin
As of 4:30 PM 12/11/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Snapshot

Open
--
Previous Close
$113.00
Day High
--
Day Low
--
52 Week High
07/28/14 - $144.75
52 Week Low
12/11/14 - $113.00
Market Cap
1.2B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
9.2M
EX-Date
03/13/15
P/E TM
--
Dividend
$5.06
Dividend Yield
0.82%
Current Stock Chart for ALK-ABELLO A/S (AKBLF)

Related News

No related news articles were found.

alk-abello a/s (AKBLF) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (AKBLF) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,844 Employees
Last Reported Date: 02/9/15
Founded in 1923

alk-abello a/s (AKBLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (AKBLF) Key Developments

ALK and Biocsl Enter into a Partnership

ALK and bioCSL announce a partnership in Australia and New Zealand which grants bioCSL exclusive rights to promote and sell ALK's SLIT-tablets against house dust mite and grass pollen allergy, and ALK's Jext(r) adrenaline auto-injector. ALK and bioCSL have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK's sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX(r) in Europe and GRASTEK(r) in North America), and its adrenaline auto-injector, Jext(r). ALK will be responsible for product supply and bioCSL will undertake registration and commercialisation of the products. As part of the agreement, ALK will receive a minor upfront payment of an undisclosed amount, followed by a milestone payment upon approval of the HDM SLIT-tablet in Australia. ALK will sell products to bioCSL at a pre-agreed price structure ensuring a certain split of the final in-market revenues generated by bioCSL. The partnership with bioCSL advances ALK's strategy of broadening its geographical presence through partnerships, acquisitions or by establishing its own affiliates.

ALK-Abelló A/S Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

ALK-Abelló A/S announced consolidated unaudited earnings results for the fourth quarter and audited consolidated and parent earnings results for the year ended December 31, 2014. For the year on consolidated basis, the company reported revenue of DKK 2,433 million against DKK 2,244 million a year ago. Operating profit (EBIT) before special items was DKK 313 million against DKK 131 million a year ago. Operating profit (EBIT) was DKK 264 million against DKK 109 million a year ago. Profit before tax (EBT) was DKK 300 million against DKK 104 million a year ago. Net profit was DKK 181 million against DKK 61 million a year ago. Earnings per share diluted was­ DKK 18.32 against DKK 6.24 a year ago. Cash flow from operating activities was DKK 320 million against DKK 146 million a year ago. Additions, intangible assets were DKK 36 million against DKK 67 million a year ago. Additions, tangible assets were DKK 166 million against DKK 186 million a year ago. Operating profit before depreciation and amortization (EBITDA) before special items was DKK 453 million against DKK 258 million for the same period a year ago. Operating profit before depreciations (EBITDA) was DKK 404 million against DKK 236 million for the same period a year ago. Cash flow from operating activities was DKK 320 million or DKK 33 per share against DKK 146 million or DKK 15 per share for the same period a year ago. Net profit, continuing operations was DKK 181 million or DKK 19 per basic and diluted share against DKK 61 million or DKK 6 per basic and diluted share for the same period a year ago. Return on equity (ROE) was 8% against 3% for the same period a year ago. For the quarter on consolidated basis, the company reported revenue of DKK 612 million, operating profit (EBIT) before special items was DKK 38 million, operating profit (EBIT) was DKK 19 million, profit before tax (EBT) was DKK 21 million, net profit was DKK 16 million, earnings per share diluted were DKK 2, EBITDA before special items of DKK 76 million, operating profit before depreciations (EBITDA) was DKK 57 million. Cash flow from operating activities was DKK 157 million or DKK 16 per share. On parent basis, for the year, the company reported revenue of DKK 941 million against DKK 791 million a year ago. Operating loss (LBIT) was DKK 7 million against DKK 132 million a year ago. Profit before tax (LBT) was DKK 108 million against loss before income tax of DKK 62 million a year ago. Net profit was DKK 106 million against net loss of DKK 27 million a year ago. For the year 2015, the company expects to grow revenue in the base business by 0-5% to DKK 2.2-2.3 billion, operating profit (EBITDA before special items), excluding revenues from sales royalties and milestone payments to be in the range of DKK 225-300 million. The company expects R& D expense to be DKK 400 million, capex to be 200 million and free cash flow to be in the range of negative DKK 100 million to DKK 200 million.

ALK-Abelló A/S, 2014 Earnings Call, Feb 09, 2015

ALK-Abelló A/S, 2014 Earnings Call, Feb 09, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $113.00 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 24.50 GBp +0.25
DBV Technologies SA €39.01 EUR -0.51
Merck & Co Inc $58.96 USD +0.47
Sanofi €87.54 EUR -1.56
Stallergenes SA €58.00 EUR -0.20
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 39.1x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 36.4x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.